Skip to main content

Feature article - A CDMO’s insight into the M&A landscape

Mark Quick, EVP of  corporate development at Recipharm, discusses the M&A trend within the CDMO industry

M&A activity within the pharmaceutical industry remains at a high. According to Ernst & Young (EY), M&A strategies have increased by around 12% year-on-year since 2012.1 CDMOs are some of the major players in these high-value deals, seeing it as a valuable strategy that enables to capitalise on another company’s strengths and thus better position their organisations to meet market demands and realise a more competitive edge.

Ascensus to buy Callery

Ascensus Specialties, which claims to be the largest global producer of dry and liquid sodium borohydride (SBH), has agreed to acquire Callery from private equity firm, Edgewater Capital.
Subscribe to M&A

 

 

 

AMRI banner advert